Skip to main content
Clinical Trials/NCT01834066
NCT01834066
Unknown
Phase 1

Safety and Efficacy of Bone Marrow Autologous Cells in Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial

Chaitanya Hospital, Pune1 site in 1 country25 target enrollmentSeptember 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Muscular Dystrophy
Sponsor
Chaitanya Hospital, Pune
Enrollment
25
Locations
1
Primary Endpoint
Significant Improvement in Muscle strength by using Kinetics Muscle testing or by using MMT( manual muscle test }score
Last Updated
11 years ago

Overview

Brief Summary

This Study is single arm, single centre trial to check the safety and efficacy of Bone Marrow derived autologous cell(100 million per dose) for the patient with Duchenne Muscular Dystrophy.

Detailed Description

Muscular dystrophy is a group of inherited disorders that involve muscle weakness and loss of muscle tissue, which get worse over time. Duchenne muscular dystrophy is caused by a defective gene for dystrophin (a protein in the muscles). However, it often occurs in people without a known family history of the condition. slowly progress diseases.it causes Muscle weaknesses, Difficulty with motor skills ,Progressive difficulty walking.Breathing difficulties and heart disease,Frequent falls,weak limbs,lose motor Function.Begins in the legs and pelvis, but also occurs less severely in the arms, neck, and other areas of the body.Trouble getting up from a lying position or climbing stairs.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
December 2016
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Chaitanya Hospital, Pune
Responsible Party
Principal Investigator
Principal Investigator

Dr. Sachin Jamadar

C0- Investigator

Chaitanya Hospital, Pune

Eligibility Criteria

Inclusion Criteria

  • Patient with Diagnose of Duchenne Muscular Dystrophy.
  • Aged in between 6 to 25 Years.
  • Willingness to undergo Bone Marrow derived Autologous cell Therapy.
  • Ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required Informed Consent form(ICF) for the study.
  • Ability and willingness to regular visit to hospital for protocol procedures and follow up

Exclusion Criteria

  • Patient who is not Diagnose of Duchenne Muscular Dystrophy.
  • Patient with History of Immunodeficiency HIV+,Hepatitis B ,HBV and TPPA+,Tumor Markers+
  • History of Life threatening allergic or immune -Mediated Reaction.
  • the site of bone marrow aspiration potentially limiting Procedure.
  • Alcohol and drug abuse / dependence.
  • Patients with History of Hypertension and Hypersensitive.

Outcomes

Primary Outcomes

Significant Improvement in Muscle strength by using Kinetics Muscle testing or by using MMT( manual muscle test }score

Time Frame: 6 Months

Secondary Outcomes

  • -Improvement of daily living scale and baseline in EMG(electromyography)(6 months)

Study Sites (1)

Loading locations...

Similar Trials